BioSpace News Archive

Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19

CENTOGENE, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced the expansion of its Senior Leadership Team with the appointment of Angelos Baxevanis as Senior Vice President Communication and Marketing.

Alexion Pharmaceuticals, Inc. announced financial results for the first quarter of 2020.

Amicus Therapeutics a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases announced the acceptance of several abstracts for presentation at the American Society of Gene & Cell Therapy 23rd Annual Meeting being held virtually on May 12 – 15.

Company will award approximately 20 grants totaling up to $100,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families

Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 3,500 shares of Calithera’s common stock, at a per share exercise price of $6.13, the closing trading price on April 30, 2020.

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced its first-quarter 2020 financial results.

Viela Bio announced it will host a webcast and conference call on Wednesday, May 13, 2020 at 5:00 p.m. ET to discuss its first quarter 2020 financial results and program highlights.

Encouraging signals of durable disease control, including confirmed partial responses in ongoing COM701 Phase 1 dose escalation study